News Release

June 17, 2008

JENEX ANNOUNCES 1,420,000 UNITS CLOSES IN FIRST TRANCHE OF PRIVATE PLACEMENT

Burlington, Ontario – The Jenex Corporation (“Jenex” or the “Corporation”) TSX Venture Exchange: JEN, Frankfurt: JNX) announces it has closed the first tranche of 1,420,000 units of their previously announced non-brokered Private Placement.

Each Unit will consist of one common share and one half of one share purchase warrant to purchase one whole share for $0.12 for a period of 12 months.

Proceeds will be used for general operating purposes.

The Private Placement will be subject to the customary four month hold period from date of issue and TSX-V approval.

About The Jenex Corporation

Jenex has a non-invasive Medical Device that prevents cold sore outbreaks. The interceptCS™ Cold Sore Prevention System is approved in Canada and has received CE approval for European Union countries.

In addition to interceptCS, Jenex markets Therapik® for insect stings & bites. Therapik immediately relieves the pain & itch caused by over 20,000 different insects. Therapik is approved in Canada and the United States and Australia, as well as having CE Mark approval in the European Union countries.

Jenex's Thermal Therapy technology is patented in the U.S, Canada, Australia, & Europe.

For further information on The Jenex Corporation contact:

Michael A. Jenkins,

Tele:(905) 632-3830

Facsimile: (905) 632-3774  

Email: jenex@jenexcorp.com

www.JenexCorp.com

www.interceptCS.com

The TSX Venture Exchange Inc. has not reviewed and does not accept responsibility for the accuracy or the contents of this press release. Certain information included in this press release is forward-looking and is subject to important risks and uncertainties. The results or events predicted in these statements may differ materially from actual results or events